WEKO3
アイテム
Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma
https://repo.qst.go.jp/records/75677
https://repo.qst.go.jp/records/7567739e0d0e2-29aa-4a14-84e1-e6405362f641
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2019-03-01 | |||||
| タイトル | ||||||
| タイトル | Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Sudo, Hitomi
× Sudo, Hitomi× Tsuji, Atsushi× Sugyo, Aya× Saga, Tsuneo× K Kaneko, Mika× Kato, Yukinari× Higashi, Tatsuya× Sudo, Hitomi× Tsuji, Atsushi× Sugyo, Aya× Higashi, Tatsuya |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity, and is applicable for radioimmunotherapy (RIT) to enhance the antitumor effect. In the present study, we evaluated the in vivo and in vitro properties of radiolabeled NZ-12 and the antitumor effect of RIT with Y-labeled NZ-12 in an NCI-H226 (H226) malignant mesothelioma xenograft mouse model. In-labeled NZ-12 bound specifically to H226 cells with high affinity, and accumulation was high in H226 tumors but low in major organs. RIT with Y-labeled NZ-12 significantly suppressed tumor growth and prolonged survival without body weight loss and obvious adverse effects. Higher podoplanin expression levels were observed in human mesothelioma specimens, suggesting higher tumor accumulation of Y-labeled NZ-12 in patients compared with the H226 tumor xenografts. Our findings suggest that Y-labeled NZ-12 is a promising RIT agent as a new therapeutic option for malignant mesothelioma that warrants further clinical studies to evaluate the dosimetry and efficacy in patients. This article is protected by copyright. All rights reserved. | |||||
| 書誌情報 |
Cancer Science 巻 110, 号 5, p. 1653-1664, 発行日 2019-02 |
|||||
| 出版者 | ||||||
| 出版者 | 日本癌学会 | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1349-7006 | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 30801908 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1111/cas.13979 | |||||
